C R Dunstan Selected Research

Osteoprotegerin

1/2007	RANK ligand.
6/2006	The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.
1/2004	The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.
12/2001	Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
10/2001	Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
7/2001	Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.
7/2001	The effects of osteoprotegerin on the mechanical properties of rat bone.
6/2001	Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
2/2001	Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.
2/2001	The effect of a single dose of osteoprotegerin in postmenopausal women.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

C R Dunstan Research Topics

Disease

11	Bone Resorption 01/2014 - 01/2000
6	Osteoporosis 07/2005 - 01/2000
3	Neoplasm Metastasis (Metastasis) 01/2007 - 06/2001
3	Neoplasms (Cancer) 01/2004 - 02/2000
3	Osteopetrosis 08/2000 - 01/2000
2	Prostatic Neoplasms (Prostate Cancer) 01/2004 - 10/2001
2	Metabolic Bone Diseases (Osteopenia) 10/2001 - 05/2000
2	Hypercalcemia (Milk Alkali Syndrome) 02/2000 - 02/2000
1	Postmenopausal Osteoporosis 01/2014
1	Rheumatoid Arthritis 06/2006
1	Multiple Myeloma 12/2001
1	Bone Diseases (Bone Disease) 12/2001
1	Osteolysis 06/2001
1	Vascular Diseases (Vascular Disease) 01/2001
1	Vascular Calcification 08/2000
1	Cachexia 02/2000
1	Humoral Hypercalcemia Of Malignancy 02/2000

Drug/Important Bio-Agent (IBA)

15	OsteoprotegerinIBA 01/2007 - 01/2000
3	RANK LigandIBA 01/2007 - 01/2000
2	Biological ProductsIBA 10/2001 - 01/2000
2	Proteins (Proteins, Gene)FDA Link 10/2001 - 07/2001
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2001 - 02/2000
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 02/2001 - 02/2000
1	Pharmaceutical PreparationsIBA 01/2014
1	Monoclonal AntibodiesIBA 01/2014
1	Denosumab FDA Link 01/2014
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2004
1	Bone Density Conservation AgentsIBA 10/2001
1	glutamyl- lysyl- alanyl- histidyl- aspartyl- glycyl- glycyl- arginineIBA 10/2001
1	deoxypyridinolineIBA 02/2001
1	collagen type I trimeric cross-linked peptideIBA 02/2001
1	Biomarkers (Surrogate Marker)IBA 02/2001
1	Estrogens (Estrogen)FDA Link 02/2001
1	CollagenIBA 02/2001
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2001
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2001
1	MineralsIBA 05/2000
1	Hormones (Hormone)IBA 02/2000
1	Parathyroid Hormone-Related ProteinIBA 02/2000
1	Recombinases (Recombinase)IBA 02/2000
1	CalciumIBA 02/2000
1	Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)IBA 02/2000
1	CytokinesIBA 02/2000
1	Complementary DNA (cDNA)IBA 02/2000

Therapy/Procedure

3	Therapeutics 07/2005 - 06/2001
1	Ovariectomy (Oophorectomy) 02/2001
1	Organ Transplantation 01/2001
1	Transplantation 02/2000